Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer
02 oct. 2023 08h00 HE
|
Solid Biosciences Inc.
- Dr. Brooks is a veteran drug development leader whose experience includes roles at Pfizer, 4D Molecular Therapeutics, and Gilead Life Sciences, which directly supports Solid’s focus on both...
Solid Biosciences to Participate at Upcoming Investor Conferences
20 sept. 2023 08h00 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences to Participate at Upcoming Investor Conferences
05 sept. 2023 08h56 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences to Participate in Citi’s 18th Annual BioPharma Conference
31 août 2023 08h00 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences Provides Second Quarter Business Update and Financial Results
14 août 2023 16h17 HE
|
Solid Biosciences Inc.
– On track to submit IND in Q4 2023 for SGT-003, a next-generation gene therapy for patients with Duchenne muscular dystrophy (Duchenne) – – Executed licensing agreement for development and...
Solid Biosciences to Participate at the Jefferies Healthcare Conference
01 juin 2023 08h00 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences to Participate at the Barclays Gene Editing & Therapy Summit
22 mai 2023 08h00 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting
16 mai 2023 08h00 HE
|
Solid Biosciences Inc.
— Oral presentation highlighting data from multiple animal models demonstrated administration of AVB-202 resulted in frataxin (FXN) expression in cardiac and central nervous system (CNS) tissues with...
Solid Biosciences Provides First Quarter Business Update and Financial Results
11 mai 2023 07h30 HE
|
Solid Biosciences Inc.
– Company remains on track to submit IND in Q4 2023 for SGT-003, a next-generation gene therapy for patients with Duchenne muscular dystrophy (Duchenne) – – Company ends first quarter with...
Solid Biosciences to Present at JMP Securities Life Sciences Conference
08 mai 2023 16h05 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...